Skip to main content

Publisher: Wiley-Blackwell on behalf of the International Society on Thrombosis and Haemostasis

Volume 10, Number 4, 1 April 2012

Free Content Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta‐analysis
pp. 512-520(9)
Authors: WARKENTIN, A. E.; DONADINI, M. P.; SPENCER, F. A.; LIM, W.; CROWTHER, M.

Favourites:
ADD

Free Content Reversal of the anti‐platelet effects of aspirin and clopidogrel
pp. 521-528(8)
Authors: LI, C.; HIRSH, J.; XIE, C.; JOHNSTON, M. A.; EIKELBOOM, J. W.

Favourites:
ADD

Free Content Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS‐PCI study
pp. 529-542(14)
Authors: SILLER‐MATULA, J. M.; DELLE‐KARTH, G.; LANG, I. M.; NEUNTEUFL, T.; KOZINSKI, M.; KUBICA, J.; MAURER, G.; LINKOWSKA, K.; GRZYBOWSKI, T.; HUBER, K.; JILMA, B.

Favourites:
ADD
Favourites:
ADD

Free Content Genetic determinants of von Willebrand factor plasma levels and the risk of stroke: the Rotterdam Study
pp. 550-556(7)
Authors: VAN SCHIE, M. C.; WIEBERDINK, R. G.; KOUDSTAAL, P. J.; HOFMAN, A.; IKRAM, M. A.; WITTEMAN, J. C. M.; BRETELER, M. M. B.; LEEBEEK, F. W. G.; DE MAAT, M. P. M.

Favourites:
ADD

Free Content Coronary artery bypass graft surgery up‐regulates genes involved in platelet aggregation
pp. 557-563(7)
Authors: REILLY, S.‐J.; LI, N.; LISKA, J.; EKSTRÖM, M.; TORNVALL, P.

Favourites:
ADD

Free Content Silent pulmonary embolism in patients with proximal deep vein thrombosis in the lower limbs
pp. 564-571(8)
Authors: TZORAN, I.; SAHAROV, G.; BRENNER, B.; DELSART, D.; ROMÁN, P.; VISONÁ, A.; JIMÉNEZ, D.; MONREAL, M.; THE RIETE INVESTIGATORScr9

Favourites:
ADD

Free Content D‐dimer threshold increase with pretest probability unlikely for pulmonary embolism to decrease unnecessary computerized tomographic pulmonary angiography
pp. 572-581(10)
Authors: KLINE, J. A.; HOGG, M. M.; COURTNEY, D. M.; MILLER, C. D.; JONES, A. E.; SMITHLINE, H. A.

Favourites:
ADD

Free Content D‐dimer testing in the diagnosis of cerebral vein thrombosis: a systematic review and a meta‐analysis of the literature
pp. 582-589(8)
Authors: DENTALI, F.; SQUIZZATO, A.; MARCHESI, C.; BONZINI, M.; FERRO, J. M.; AGENO, W.

Favourites:
ADD

Free Content INR targets and site‐level anticoagulation control: results from the Veterans AffaiRs Study to Improve Anticoagulation (VARIA)
pp. 590-595(6)
Authors: ROSE, A. J.; BERLOWITZ, D. R.; MILLER, D. R.; HYLEK, E. M.; OZONOFF, A.; ZHAO, S.; REISMAN, J. I.; ASH, A. S.

Favourites:
ADD

Free Content Failure to correct International Normalized Ratio and mortality among patients with warfarin‐related major bleeding: an analysis of electronic health records
pp. 596-605(10)
Authors: MENZIN, J.; HOESCHE, J.; FRIEDMAN, M.; NICHOLS, C.; BERGMAN, G. E.; CROWTHER, M.; GARCIA, D.; JONES, C.

Favourites:
ADD

Free Content Long‐term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users
pp. 606-614(9)
Authors: VERHOEF, T. I.; REDEKOP, W. K.; BUIKEMA, M. M.; SCHALEKAMP, T.; VAN DER MEER, F. J. M.; LE CESSIE, S; WESSELS, J. A. M.; VAN SCHIE, R. M. F.; DE BOER, A.; TEICHERT, M.; VISSER, L. E.; MAITLAND‐VAN DER ZEE, A. H.; ON BEHALF OF THE EU‐PACT GROUPcr13

Favourites:
ADD

Free Content Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders
pp. 615-621(7)
Authors: PEYVANDI, F.; PALLA, R.; MENEGATTI, M.; SIBONI, S. M.; HALIMEH, S.; FAESER, B.; PERGANTOU, H.; PLATOKOUKI, H.; GIANGRANDE, P.; PEERLINCK, K.; CELKAN, T.; OZDEMIR, N.; BIDLINGMAIER, C.; INGERSLEV, J.; GIANSILY‐BLAIZOT, M.; SCHVED, J. F.; GILMORE, R.; GADISSEUR, A.; BENEDIK‐DOLNIČAR, M.; KITANOVSKI, L.; MIKOVIC, D.; MUSALLAM, K. M.; ROSENDAAL, F. R.; ON BEHALF OF THE EUROPEAN NETWORK OF RARE BLEEDING DISORDERS (EN‐RBD) GROUPcr24

Favourites:
ADD

Free Content Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)
pp. 622-631(10)
Authors: KNOEBL, P.; MARCO, P.; BAUDO, F.; COLLINS, P.; HUTH‐KÜHNE, A.; NEMES, L.; PELLEGRINI, F.; TENGBORN, L.; LÉVESQUE, H.; ON BEHALF OF THE EACH2 REGISTRY CONTRIBUTORScr10

Favourites:
ADD

Free Content Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patients
pp. 632-638(7)
Authors: CASTAMAN, G.; FEDERICI, A. B.; TOSETTO, A.; LA MARCA, S.; STUFANO, F.; MANNUCCI, P. M.; RODEGHIERO, F.

Favourites:
ADD

Free Content The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus
pp. 639-646(8)
Authors: LEMKES, B. A.; BÄHLER, L.; KAMPHUISEN, P. W.; STROOBANTS, A. K.; VAN DEN DOOL, E. J.; HOEKSTRA, J. B.; NIEUWLAND, R.; GERDES, V. E.; HOLLEMAN, F.

Favourites:
ADD

Free Content Human neutrophil alpha‐defensins induce formation of fibrinogen and thrombospondin‐1 amyloid‐like structures and activate platelets via glycoprotein IIb/IIIa
pp. 647-661(15)
Authors: HORN, M.; BERTLING, A.; BRODDE, M. F.; MÜLLER, A.; ROTH, J.; VAN AKEN, H.; JURK, K.; HEILMANN, C.; PETERS, G.; KEHREL, B. E.

Favourites:
ADD

Free Content Diurnal expression of the thrombopoietin gene is regulated by CLOCK
pp. 662-669(8)
Authors: TRACEY, C. J.; PAN, X.; CATTERSON, J. H.; HARMAR, A. J.; HUSSAIN, M. M.; HARTLEY, P. S.

Favourites:
ADD

Free Content The profibrotic cytokine transforming growth factor‐β1 increases endothelial progenitor cell angiogenic properties
pp. 670-679(10)
Authors: EVRARD, S. M.; D′AUDIGIER, C.; MAUGE, L.; ISRAËL‐BIET, D.; GUERIN, C. L.; BIECHE, I.; KOVACIC, J. C.; FISCHER, A.‐M.; GAUSSEM, P.; SMADJA, D. M.

Favourites:
ADD

Free Content Circulating microparticles and endothelial progenitor cells in atherosclerosis: pharmacological effects of irbesartan
pp. 680-691(12)
Authors: GEORGESCU, A.; ALEXANDRU, N.; ANDREI, E.; TITORENCU, I.; DRAGAN, E.; TARZIU, C.; GHIORGHE, S.; BADILA, E.; BARTOS, D.; POPOV, D.

Favourites:
ADD

Free Content Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy
pp. 692-694(3)
Authors: SPYROPOULOS, A. C.; DOUKETIS, J. D.; GEROTZIAFAS, G.; KAATZ, S.; ORTEL, T. L.; SCHULMAN, S.; ON BEHALF OF THE SUBCOMMITTEE ON CONTROL OF ANTICOAGULATION OF THE SSC OF THE ISTHcr7

Favourites:
ADD

Free Content Recommendations for the implementation of platelet autoantibody testing in clinical trials of immune thrombocytopenia
pp. 695-697(3)
Authors: ARNOLD, D. M.; SANTOSO, S.; GREINACHER, A.; ON BEHALF OF THE PLATELET IMMUNOLOGY SCIENTIFIC SUBCOMMITTEE OF THE ISTHcr4

Favourites:
ADD

Free Content Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH
pp. 698-702(5)
Authors: BAGLIN, T.; BAUER, K.; DOUKETIS, J.; BULLER, H.; SRIVASTAVA, A.; JOHNSON, G.

Favourites:
ADD

Free Content Darexaban has high sensitivity in the prothrombin time clotting test
pp. 703-705(3)
Authors: FUNATSU, T.; IWATSUKI, Y.; KAKU, S.

Favourites:
ADD

Free Content Low‐titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half‐life after immune tolerance induction
pp. 706-708(3)
Authors: DARDIKH, M.; ALBERT, T.; MASEREEUW, R.; OLDENBURG, J.; NOVAKOVA, I.; VAN HEERDE, W. L.; VERBRUGGEN, B.

Favourites:
ADD
Favourites:
ADD

Free Content Early platelet activation, inflammation and acute brain injury after a subarachnoid hemorrhage: a pilot study
pp. 711-713(3)
Authors: FRONTERA, J. A.; ALEDORT, L.; GORDON, E.; EGOROVA, N.; MOYLE, H.; PATEL, A.; BEDERSON, J. B.; SEHBA, F.

Favourites:
ADD

Free Content Discrepancy of the international normalized ratio observed in the external quality assessment survey: a cause for concern
pp. 714-716(3)
Authors: TRIPODI, A.; CHANTARANGKUL, V.; LEGNANI, C.; FRONTONI, R.; TESTA, S.

Favourites:
ADD
Favourites:
ADD

Free Content Genetic variation in F3 (tissue factor) and the risk of incident venous thrombosis: meta‐analysis of eight studies
pp. 719-722(4)
Authors: SMITH, N. L.; HEIT, J. A.; TANG, W.; TEICHERT, M.; CHASMAN, D. I.; MORANGE, P.‐E.; ON BEHALF OF THE VENOUS THROMBOSIS GENETIC REPLICATION CONSORTIUMcr7

Favourites:
ADD

Free Content Factor XIII plasma levels in women with unexplained recurrent pregnancy loss
pp. 723-725(3)
Authors: PASQUIER, E.; DE SAINT MARTIN, L.; KOHLER, H. P.; SCHROEDER, V.

Favourites:
ADD

Free Content Convalescent plasma levels of TAFI activation peptide predict death and recurrent vascular events in ischemic stroke survivors
pp. 725-727(3)
Authors: JOOD, K.; REDFORS, P.; GILS, A.; BLOMSTRAND, C.; DECLERCK, P. J.; JERN, C.

Favourites:
ADD

Free Content von Willebrand factor propeptide to antigen ratio in acquired thrombotic thrombocytopenic purpura
pp. 728-730(3)
Authors: STUFANO, F.; LA MARCA, S.; PONTIGGIA, S.; MUSALLAM, K. M.; PEYVANDI, F.

Favourites:
ADD

Free Content Heparin concentrations in neonates during cardiopulmonary bypass
pp. 730-732(3)
Authors: DAVIDSON, S. J.; TILLYER, M. L.; KEOGH, J.; HALL, J.; KELLEHER, A. A.

Favourites:
ADD

Free Content Role of factor V Leiden or G20210A prothrombin mutation in patients with symptomatic pulmonary embolism and deep vein thrombosis: a meta‐analysis of the literature
pp. 732-737(6)
Authors: DENTALI, F.; AGENO, W.; BOZZATO, S.; MALATO, A.; GIANNI, M.; SQUIZZATO, A.; PRISCO, D.

Favourites:
ADD

Free Content Join ISTH
pp. 738-739(2)

Favourites:
ADD

Free Content Corrigendum
pp. 740-740(1)

Favourites:
ADD

  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more